Literature DB >> 36192661

Bone marrow involvement is a risk factor for infusion-related reactions in patients with follicular lymphoma treated by obinutuzumab.

Yosuke Masamoto1, Kazuki Taoka1, Hiroaki Maki1, Mineo Kurokawa2,3.   

Abstract

Entities:  

Keywords:  Follicular lymphoma; Infusion-related reactions; Obinutuzumab; Risk factors

Year:  2022        PMID： 36192661     DOI： 10.1007/s00277-022-04987-5

Source DB:  PubMed          Journal:  Ann Hematol        ISSN： 0939-5555            Impact factor:   4.030


× No keyword cloud information.
  10 in total

1.  Cytokine release in patients with CLL treated with obinutuzumab and possible relationship with infusion-related reactions.

Authors:  Ciara L Freeman; Franck Morschhauser; Laurie Sehn; Mark Dixon; Richard Houghton; Thierry Lamy; Günter Fingerle-Rowson; Elisabeth Wassner-Fritsch; John G Gribben; Michael Hallek; Gilles Salles; Guillaume Cartron
Journal:  Blood       Date:  2015-10-07       Impact factor: 22.113

2.  A clinical prediction model for infusion-related reactions to rituximab in patients with B cell lymphomas.

Authors:  Tatsuya Hayama; Katsuhiro Miura; Akihiro Uchiike; Masaru Nakagawa; Daisuke Tsutsumi; Masashi Sakagami; Yoshikazu Yoshida; Masami Takei
Journal:  Int J Clin Pharm       Date:  2017-01-31

3.  Adverse drug reactions after intravenous rituximab infusion are more common in hematologic malignancies than in autoimmune disorders and can be predicted by the combination of few clinical and laboratory parameters: results from a retrospective, multicenter study of 374 patients.

Authors:  Giovanni D'Arena; Vittorio Simeon; Luca Laurenti; Michele Cimminiello; Idanna Innocenti; Michele Gilio; Angela Padula; Maria Luigia Vigliotti; Sonya De Lorenzo; Giacomo Loseto; Anna Passarelli; Matteo Nicola Dario Di Minno; Marco Tucci; Vincenzo De Feo; Fiorella D'Auria; Francesco Silvestris; Giovanni Di Minno; Pellegrino Musto
Journal:  Leuk Lymphoma       Date:  2017-04-03

4.  Purging with chlorambucil to prevent infusion-related reaction before obinutuzumab administration: A monocentric pilot experience.

Authors:  Francesco Autore; Alberto Fresa; Idanna Innocenti; Annamaria Tomasso; Francesca Morelli; Andrea Corbingi; Federica Sorà; Luca Laurenti
Journal:  Hematol Oncol       Date:  2019-11-07       Impact factor: 5.271

5.  Obinutuzumab plus bendamustine versus bendamustine monotherapy in patients with rituximab-refractory indolent non-Hodgkin lymphoma (GADOLIN): a randomised, controlled, open-label, multicentre, phase 3 trial.

Authors:  Laurie H Sehn; Neil Chua; Jiri Mayer; Gregg Dueck; Marek Trněný; Kamal Bouabdallah; Nathan Fowler; Vincent Delwail; Oliver Press; Gilles Salles; John Gribben; Anne Lennard; Pieternella J Lugtenburg; Natalie Dimier; Elisabeth Wassner-Fritsch; Günter Fingerle-Rowson; Bruce D Cheson
Journal:  Lancet Oncol       Date:  2016-06-23       Impact factor: 41.316

6.  Bone marrow involvement is predictive of infusion-related reaction during rituximab administration in patients with B cell lymphoma.

Authors:  Junshik Hong; Ji Yeon Kim; Hee Kyung Ahn; Sang-Min Lee; Sun Jin Sym; Jinny Park; Eun Kyung Cho; Jeong Yeal Ahn; Sanghui Park; Sang Pyo Lee; Dong Bok Shin; Jae Hoon Lee
Journal:  Support Care Cancer       Date:  2012-10-31       Impact factor: 3.603

7.  Obinutuzumab for the First-Line Treatment of Follicular Lymphoma.

Authors:  Robert Marcus; Andrew Davies; Kiyoshi Ando; Wolfram Klapper; Stephen Opat; Carolyn Owen; Elizabeth Phillips; Randeep Sangha; Rudolf Schlag; John F Seymour; William Townsend; Marek Trněný; Michael Wenger; Günter Fingerle-Rowson; Kaspar Rufibach; Tom Moore; Michael Herold; Wolfgang Hiddemann
Journal:  N Engl J Med       Date:  2017-10-05       Impact factor: 91.245

8.  Bone Marrow Infiltration Is a Distinctive Risk Factor for Rituximab Infusion-Related Reactions in CD20-Positive B-Cell Non-Hodgkin Lymphoma.

Authors:  Shinya Ohata; Kei Takenaka; Daisuke Sugiyama; Takeshi Sugimoto
Journal:  Adv Hematol       Date:  2022-02-11

9.  Role of CD20 expression and other pre-treatment risk factors in the development of infusion-related reactions in patients with CLL treated with obinutuzumab.

Authors:  C L Freeman; M Dixon; R Houghton; K-A Kreuzer; G Fingerle-Rowson; M Herling; K Humphrey; S Böttcher; C S de Costa; V Iglesias; S Stilgenbauer; J Gribben; M Hallek; V Goede
Journal:  Leukemia       Date:  2016-03-04       Impact factor: 11.528

10.  Clinical significance of rituximab infusion-related reaction in diffuse large B-cell lymphoma patients receiving R-CHOP.

Authors:  Kyoung Min Cho; Bhumsuk Keam; Hyerim Ha; Miso Kim; Jae-Woo Jung; Woo-Jung Song; Tae Min Kim; Yoon Kyung Jeon; Hye-Ryun Kang; Dong-Wan Kim; Chul Woo Kim; Dae Seog Heo
Journal:  Korean J Intern Med       Date:  2017-11-20       Impact factor: 2.884
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.